Sign in10 stories
The application, based on the Phase III SAFFRON trial, targets patients who progressed on EGFR-TKI therapy with MET overexpression or amplification.
SEC filing (2)
HUTCHMED will get $110 million upfront as GSK takes global rights outside Greater China to the KRAS-EGFR conjugate HMPL-A830, with milestone figures stated differently across the filing.
SEC filing
China's regulator granted conditional approval for fanregratinib in pretreated intrahepatic cholangiocarcinoma patients with FGFR2 fusion or rearrangement.
SEC filing
HUTCHMED said a medical device firm where Chairman Dan Eldar previously served as director has entered insolvency proceedings in Israel.
SEC filing
The trial showed statistically significant progression-free and overall survival gains for ORPATHYS plus TAGRISSO versus chemotherapy in MET-driven resistant NSCLC.
SEC filing
Net income fell to $15.9 million from $455.0 million a year earlier, a decline driven by a large one-time gain in 2025, while ELUNATE and SULANDA sales each grew over 40%.
SEC filing